Article: Somaxon Pharmaceuticals' SILENOR(TM) Demonstrates Positive Results in Its Third Phase 3 Clinical Trial in Insomnia.

Article: Somaxon Pharmaceuticals Announces Positive Phase 3 Results with ...
PR Newswire;  April 10, 2006 ;     700+ words ...- SILENOR(TM) demonstrated statistically significant ... with the tested doses of 3 mg and 6 mg of SILENOR(TM) (doxepin HCl), achieving statistically ... setting, were significant for both doses. SILENOR(TM) demonstrated improvement in mean WASO ...

Article: Somaxon Pharmaceuticals Provides Update on Preclinical and ...
PR Newswire;  September 11, 2006 ;     700+ words ... ... Drug Administration (FDA) for SILENOR(TM) (doxepin HCl), the company ... requested carcinogenicity studies of SILENOR(TM) as a post-New Drug Application ... reproductive toxicology studies of SILENOR(TM) requested by the FDA and plans ...

Article: Somaxon Pharmaceuticals Announces Completion of 26-Week ...
Business Wire;  January 9, 2008 ;     700+ words ...* SILENOR[TM] NDA Submission Planned by Mid-February ... pharmaceutical ingredient in its product candidate SILENOR[TM]. Based on the results of this study ... submission of a New Drug Application for SILENOR[TM], which is now estimated to occur by ...

Article: Somaxon's SILENOR(TM) Demonstrates Positive Results ...
Business Wire;  December 18, 2006 ;     700+ words ...* SILENOR[TM] Demonstrates Statistically Significant ... Represents Fourth Phase 3 Clinical Trial of SILENOR[TM] to Demonstrate Positive Results in the ... s Phase 3 clinical trial evaluating SILENOR[TM] (doxepin HCl) in elderly patients ...

Article: Somaxon Pharmaceuticals' SILENOR(TM) Demonstrates ...
PR Newswire;  October 23, 2006 ;     700+ words ...* SILENOR(TM) Demonstrates Statistically Significant ... LPS) Demonstrates Sleep Onset Action of SILENOR(TM) * Represents Second Phase 3 Clinical Trial of SILENOR(TM) to Demonstrate Positive Results in the ...

Article: Somaxon Provides Update on SILENOR(TM) Preclinical ...
Business Wire;  February 13, 2007 ;     700+ words ... ... preclinical testing program for SILENOR[TM] (doxepin HCl), its lead product ... Drug Administration (FDA) for SILENOR[TM] in the third quarter of 2007 ... with Somaxon's assessment that SILENOR[TM] does not appear to have genotoxic ...

Article: Somaxon Pharmaceuticals Submits New Drug Application for ...
Business Wire;  January 31, 2008 ;     700+ words ... ... Drug Administration (FDA) for SILENOR[TM] (doxepin hydrochloride). Somaxon is seeking marketing approval of SILENOR[TM] for the treatment of insomnia ... completion and submission of our NDA for SILENOR[TM] represents a significant milestone ...